Tata 1mg turns EBITDA positive across core businesses

Tata 1mg, the digital healthcare platform of the Tata Group said that it has turned EBITDA positive across all its key business verticals.

According to the company, all core businesses became EBITDA positive in December 2025 and maintained profitability through the fourth quarter of FY26. The company attributed this achievement to its decade-long effort to build an integrated healthcare platform spanning pharmacy, diagnostics, specialty care, consultations, and retail healthcare.

Tata 1mg Co-founder and CEO Prashant Tandon described the year as an inflection point, noting that scale is now translating into improved customer experience and stronger unit economics.

The company’s ePharmacy business reached breakeven while continuing to expand. Express medicine delivery within 30 to 60 minutes is now available across 10 cities. Meanwhile, its diagnostics business crossed Rs 600 crore in annual recurring revenue (ARR), recording over 40% year-on-year growth and maintaining double-digit EBITDA margins. The diagnostics network includes 19 NABL-accredited laboratories serving customers in 70 cities.

Tata 1mg’s Specialty Pharma division also posted strong growth of around 65% during FY26, driven by patient support programmes, adult vaccination, cancer care and obesity management. Its direct-to-consumer health products portfolio surpassed ₹200 crore ARR and remains profitable.

On the retail front, the company has expanded its physical presence to more than 280 stores across nine clusters and plans to increase the network to over 500 outlets within the next 12 months. It is also strengthening its AI capabilities through platforms such as Health Insights Hub and Pulse, which is currently used by more than 75 pharmaceutical companies.

Looking ahead, Tata 1mg plans to focus on faster pharmacy deliveries, diagnostics expansion, specialty care partnerships and AI-driven personalised healthcare experiences.